engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes.
The company’s gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company’s technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture.
It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy.
The company has strategic partnership with Edwards Lifesciences Corporation.
Sangamo Biosciences was founded in 1995 by Edward Lanphier.
The company is headquartered in Richmond, California.
